Reserpine-induced central effects: Pharmacological evidence for the lack of central effects of reserpine methiodide

Canadian Journal of Physiology and Pharmacology

Volumn 83, Issue 6, 2005, Pages 509-515

  Nammi, Srinivas ^a,b   Boini, Krishna Murthy ^a,c   Koppula, Sushruta ^a   Sreemantula, Satyanarayana ^a  

^a ANDHRA UNIVERSITY   (India)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Behaviour; Blood pressure; Mice; Rats; Reserpine; Resperine methiodide (RMI)

Indexed keywords

CATECHOLAMINE; RESERPINE; RESERPINE DERIVATIVE; RESERPINE METHIODIDE; THIOPENTAL; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; BLOOD PRESSURE; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM DEPRESSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HYPNOSIS; HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECTUM TEMPERATURE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BLOOD PRESSURE; BODY TEMPERATURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMOBILITY RESPONSE, TONIC; MALE; MICE; MOTOR ACTIVITY; RATS; RATS, WISTAR; RESERPINE;

EID: 23844539978     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y05-039     Document Type: Article

References (39)

1. Baumeister, A.A., Hawkins, M.F., and Uzelac, S.M. 2003. The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis. J. Hist. Neurosci. 12: 207-220.
2. Beim, H.J. 1956. The pharmacology of rauwolfia. Pharmacol. Rev. 8: 435-483.
3. Beim, H.J., and Brunner, H. 1966. In Antihypertensive therapy: principles and practice. Edited by F. Gross. Springer, Berlin. pp. 15.
4. Bertler, A. 1961. Effect of reserpine on the storage of catecholamines in brain and other tissues. Acta Physiol. Scand. 51: 75-83.
5. Brewster, M.E., Biegon, A., Degani, H., and Pop, E. 1996. Mechanisms of action of quaternary derivatives of tamoxifen. In Proceedings of the American Chemical Society National Meeting, book of abstracts, 212. American Chemical Society, Orlando, Fla., August 25-29.
6. Brodie, B.B., Finer, K.F., Orlans, F.B., Quinn, G.F., and Sulser, F. 1960. Evidence that tranquilizing action of reserpine is associated with change in brain serotonin. J. Pharmacol. Exp. Ther. 129: 250-256.
7. Burn, J.H., and Rand, M.J. 1958. Noradrenaline in artery walls and its dispersal by reserpine. Br. Med. J. 1(5076): 903-908.
8. ++-ATP dependent storage mechanism in the amine granules of the adrenal medulla. Med. Exp. 6: 47-53.
9. Cook, L., and Weidley, E. 1957. Behavioral effects of some psychopharmacological agents. Ann. N.Y. Acad. Sci. 66: 740-752.
10. Desai, M.K., Dikshit, R.K., Mansuri, S.M., and Shah, U.K. 1994. Effect of nifedipine, a calcium channel inhibitor, on sedation produced by reserpine, clonidine and propranolol in mice. Indian J. Exp Biol. 32: 314-317.
11. Dutra, R.C., Audreazza, A.P., Adreatini, R., Tufik, S., and Vital, M.A. 2002. Behavioral effects of MK-801 on reserpine-treated mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26: 487-495.
12. 2 adrenergic receptors. Pharmacol. Biochem. Behav. 27: 21-24.
13. Gareri, P., De Fazio, P., and De Sarro, G. 2002. Neuropharmacology of depression in aging and age-related diseases. Aging Res. Rev. 1: 113-134.
14. 3-epimerization of reserpine and deserpidine. Tetrahedron, 23: 4053-4063.
15. Hughes, W.M., Moyer, J.H., and Daeschner, W.C. 1955. Parenteral reserpine in treatment of hypertensive emergencies. Arch. Intern. Med. 95: 563-577.
16. Janosky, D.S. 2002. Central anticholinergics to treat nerve-agent poisoning. Lancet, 359: 225-226.
17. Kastin, A.J., Honour, L.C., Sueiras-Diaz, J., and Coy, D.H. 1982. Oppostite effects of CRF and ACTH on reserpine-induced hypothermia. Pharmacol. Biochem. Behav. 17: 13-1206.
18. Khatri, C.K., Qayum, A., and Yusuf, S.M. 1982. Comparative studies on the effects of reserpine and its derivatives (bromo and dibromo) reserpine on the blood pressure, heart rate and EEG of rabbit. J. Pak. Med. Assoc. 32: 141-144.
19. Kuhn, W.L., and Van Maanen, E.F. 1961. Central nervous system effects of thalidomide. J. Pharmacol. Exp. Then 134: 60-68.
20. Lin, H.C., Yu, P.C., Lee, S.D., Tsai, Y.T., Kuo, J.S., and Yang, M.C. 1993. Effects of reserpine administration in two models of portal hypertension in rats. J. Hepatol. 19: 413-417.
21. Magadan, G.J. 1991. Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?. Gen. Intern. Med. 6: 561-572.
22. Matsuoka, M., Yoshida, H., and Imaizumi, R. 1964. Correlation between brain catecholamine and sedative action of reserpine. Nature (London), 202: 198.
23. Nammi, S., Boini, K.M., Kilari, E.K., and Sreemantula, S. 2004. Pharmacological evidence for lack of central effects of reserpine methonitrate: a novel quaternary analogue of reserpine. Therapy, 1: 231-239.
24. Noble, A. 1973. The rat blood pressure preparation. In Experiments in Physiology and Biochemistry. Vol. 6. Edited by G.A. Kernut. Academic Press, London. pp. 1-32.
25. Palfai, T., Wichlinski, L., and Brown, O.M. 1983. The effect of reserpine, syrosingopine and guanethidine on the retention of discriminated escape reversal: peripherally administered catecholamines cannot reverse the reserpine amnesia in this situation. Behav. Neural. Biol. 38: 120-126.
26. Pittrow, D.B., Krönig, B., Kirch, W., and Weidinger, G. 1996. Evaluation of reserpine and clopamid alone or in combination for first-line treatment of hypertension. Am. J. Hypertens. 9: 144.
27. Plummer, A.J., Earl, A., Schneider, A., Trapold, J., and Barrett, W. 1954. Pharmacology of rauwolfia alkaloids, including reserpine. Ann. NY. Acad. Sci. 59: 8-21.
28. Protiva, M., Rajsner, M., and Jilek, J.O. 1960. Synthesis in the Group of hypotensive alkaloids XIII. Synthesis of dl-10-methyldeserpidine, dl-10-ethoxydeserpidine and dl-10-methylthiodeserpidine. Monatsh. Chem. 91: 703-716.
29. Rudnick, G., Steiner-Mordoch, S.S., Fishkes, H., Stern-Bach, Y, and Schuldiner, S. 1990. Energetics of reserpine binding and occlusion by the chromaffin granule biogenic amine transporter. Biochemistry, 29: 603-608.
30. Salmoiraghi, G.C., Sollero, L., and Page, I.H. 1956. Blockade by brom-lysergic acid diethylamine (BOL) of the potentiating action of serotonin and reserpine on hexobarbital hypnosis. J. Pharmacol. Exp. Then 117: 166-168.
31. Schlittler, E. U.S. Patent 3,169,967, 1965.
32. Schneider, J.A, Plummer, A.J., Earl, A.E., and Gaunt, R. 1955. Neuropharmacological aspects of reserpine. Ann. N.Y. Acad. Sci. 61: 17-26.
33. Shore, P.A., Pletscher, A., Brodie, B.B. 1956. Release of platelet serotonin by reserpine: effect on homeostasis. J. Pharmacol. Exp. Then 116: 51.
34. Shore, P.A., Silver, S.L., and Brodie, B.B. 1955. Interaction of serotonin and lysergic acid diethylamide (LSD) in the central nervous system. Experientia, 11: 272-273.
35. Sreemantula, S., Boini, K.M., and Nammi, S. 2004. Reserpine methonitrate, a novel quaternary analogue of reserpine augments urinary excretion of VMA and 5-HIAA without affecting HVA in rats. BMC Pharmacol. 4: 30.
36. Sreemantula, S., Boini, K.M., Koppula, S., Kilari, E.K., and Nammi, S. 2005. Indirect biochemical evidence that reserpine methiodide produces selective depletion of peripheral biogenic amines in rats. Pharmazie, 60: 294-297.
37. Trcka, V., and Carlsson, A. 1967. Pharmacology of reserpine analogues VI. Reserpine analogs with differential effect on brain monoamines. Acta Physiol. Toxicol. 25: 107-112.
38. Turner, R.A. 1965. Ataractic (tranquillizing, neuroleptic) agents. In Screening Methods in Pharmacology. Vol. 1. Edited by R.A. Turner. Academic Press, London. pp. 87-99.
39. Varma, R.K., Kaushal, R., Thomas, G.P., Junnarkar, A.Y., Singh, P.P., and Tripathi, R.M. 1987. Evaluation of dimethyl sulfoxide as a solvent in pharmacological experiments. Indian J. Exp Biol. 25: 758-760.